Jali Medical

Jali Medical operates as a specialist distributor serving neuroscience research and clinical markets, rather than as a broad-based medical supplier or an identified device manufacturer. Its portfolio spans TMS, transcranial electrical stimulation, EEG, EMG, neuronavigation, and wearable neurotechnology. The named products include systems from Deymed and Bittium, alongside Apollo TMS Therapy and Jaltron customized coils. The company’s stated differentiators are breadth across complementary neurotechnology categories and support that extends from equipment selection and integration to scientific and regulatory guidance and onsite assistance. Its competitive context is the specialist distribution and support segment, where access to products from manufacturers such as ANT Neuro, Delsys, neuroConn, and Rogue Research contributes to portfolio breadth; these are identified as manufacturers represented in its offering, not as competitors. With a recorded employee range of 1–10 and a founding year of 1991, Jali Medical appears to have a focused operating scale and a long-standing niche presence. Its position depends on matching specialized equipment to institutional and clinical use cases, rather than on documented proprietary platform technology.

Jali Medical’s available profile indicates a long-running specialist business founded in 1991, with a recorded employee range of 1–10. Its trajectory is therefore better characterized by a sustained niche focus and portfolio breadth than by publicly documented venture-backed expansion. The product list covers several complementary areas: clinical TMS therapy, research stimulators, customized coils, and EEG systems. The broader company description also includes tES/tDCS, EMG, neuronavigation, and wearable neurotechnology. This range suggests an offering that serves multiple stages and settings in neuroscience work, from measurement and research stimulation to clinical treatment. The company’s described support services—selection, integration, guidance, and onsite assistance—may complement its distribution model, but there are no disclosed scale, revenue, or customer metrics to quantify their impact. Overall, the evidence points to continuity and specialized portfolio development, while the pace and direction of recent growth remain unclear.